Dong-Fang Yu

This inventor holds 24 USPTO granted patents and 6 published patent applications, plus 8 CIPO patents and 8 EPO patents, primarily in Imaging and Therapy. Top assignees: The University of Texas System, Pg-Txl Company, L.p., Taiwan Hopaz Chems, Mfg. Co., Ltd.. Active years: 1999-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dong-Fang Yu. Retrieved from https://idiyas.com/inventor/dong-fang-yu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 6)

% Patents Active = 66.7

CIPO Patents = 8

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 4.0

ph-index = 12

Forward Citations = 796(Granted Patents)

Company Filing History:

15 out of 5,640

The University of Texas System

Taiwan Hopaz Chems, Mfg. Co., Ltd.

patent

where one patent can have more than one assignee

Years Active: 1999-2017

Loading Chart...

Areas of Expertise:

Glycopeptide Compositions

Ethylenedicysteine Conjugates

Cellular Imaging

Myocardial Disease

Targeted Ligand Conjugates

Water Soluble Paclitaxel

Local Regional Chemotherapy

Radiotherapy

In Situ Hydrogel

Tissue Specific Imaging

Cancer Therapy

Drug Conjugates

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9820986 - Glycopeptide compositions (2017-11-21),

2. 9549995 - Efficient synthesis of ethylenedicysteine-sugar conjugates for imaging and therapy (2017-01-24),

3. 9050378 - [object Object] (2015-06-09),

4. 8758723 - Compositions and methods for cellular imaging and therapy (2014-06-24),

5. 8440168 - Image-guided therapy of myocardial disease: composition, manufacturing and applications (2013-05-14),

6. 8236279 - Bisaminoethanethiol-targeting ligand conjugates and compositions (2012-08-07),

7. 7632484 - Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging (2009-12-15),

8. 7615208 - Metal ion-labeled bis-aminoethanethiol-targeting ligand conjugates, compositions, and methods for tissue-specific disease imaging (2009-11-10),

9. 7611693 - Mechanism-based targeted pancreatic beta cell imaging and therapy (2009-11-03),

10. 7582281 - Ethylenedicysteine (EC)-drug conjugates compositions and methods for tissue specific disease imaging (2009-09-01),

11. 7384977 - Water soluble paclitaxel prodrugs (2008-06-10),

12. 7229604 - Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging (2007-06-12),

13. 7223380 - Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging (2007-05-29),

14. 7135496 - Water soluble paclitaxel derivatives (2006-11-14),

15. 7067111 - Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging (2006-06-27),

Title: Innovations and Contributions of Dong-Fang Yu in Glycopeptide Research

Introduction

Dong-Fang Yu, an esteemed inventor located in Houston, TX, has made significant contributions to the field of glycopeptides, holding an impressive total of 24 patents. His work primarily focuses on the synthesis and applications of glycopeptide compositions, showcasing his commitment to innovating therapeutic and diagnostic methods.

Latest Patents

Among his notable inventions, Yu has developed glycopeptide compositions that feature glycosides covalently bound to peptides through amide bonds. These innovative glycopeptides can be conjugated with various diagnostic or therapeutic agents, including radionuclides, which are beneficial for imaging and treatment purposes. Notably, specific embodiments involve glycopeptides composed of chitosan linked to poly(amino acids) like poly(glutamic acid) or poly(aspartic acid). The potential applications of these compositions encompass cancer treatment, rheumatoid arthritis therapy, and other critical medical interventions.

Another significant patent by Yu focuses on the efficient synthesis of ethylenedicysteine-sugar conjugates. He presents novel methods for producing these conjugates in high purity, using starting materials like thiazolidine carboxylic acid. The resulting conjugates are instrumental in diagnostic imaging for tumors and diagnosing conditions such as myocardial ischemia, highlighting their dual therapeutic and diagnostic capabilities.

Career Highlights

Dong-Fang Yu's career includes influential roles at the University of Texas System and Pg-txl Company, L.P. His innovative research and expertise in glycopeptide synthesis have positioned him as a leader in his field, contributing to advancements in medicine through his patented inventions.

Collaborations

Throughout his career, Yu has collaborated with notable individuals such as David J. Yang and Chun Li. These partnerships have enriched his research endeavors, fostering an environment of innovation and discovery.

Conclusion

In summary, Dong-Fang Yu's contributions to glycopeptide research are characterized by his extensive patent portfolio and collaborative efforts. His inventions continue to pave the way for innovative therapeutic and diagnostic applications, reflecting his pivotal role in advancing medical science.

Profile summary based on public USPTO records.